Longitudinal change of circulating tumour cell count and its relation to prognosis in advanced intrahepatic cholangiocarcinoma patients

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA registry. J Hepatol. 2022;76(5):1109–1121.
   PubMed Web of Science ®Google Scholar
• Entezari P, Riaz A. Intrahepatic cholangiocarcinoma. Semin Intervent Radiol. 2020;37(5):475–483.
   PubMed Web of Science ®Google Scholar
• Kodali S, Shetty A, Shekhar S, et al. Management of intrahepatic cholangiocarcinoma. J Clin Med. 2021;10(11):2368.
   PubMed Web of Science ®Google Scholar
• Chen X, Du J, Huang J, et al. Neoadjuvant and adjuvant therapy in intrahepatic cholangiocarcinoma. J Clin Transl Hepatol. 2022;10(3):553–563.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.
   PubMed Web of Science ®Google Scholar
• Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30(12):1950–1958.
   PubMed Web of Science ®Google Scholar
• Kim ST, Kang JH, Lee J, et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol. 2019;30(5):788–795.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-Paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5(6):824–830.
   PubMed Web of Science ®Google Scholar
• Menyailo ME, Bokova UA, Ivanyuk EE, et al. Metastasis prevention: focus on metastatic circulating tumor cells. Mol Diagn Ther. 2021;25(5):549–562.
   PubMed Web of Science ®Google Scholar
• Chemi F, Mohan S, Guevara T, et al. Early dissemination of circulating tumor cells: biological and clinical insights. Front Oncol. 2021;11:672195.
   PubMed Web of Science ®Google Scholar
• Smit DJ, Pantel K, Jucker M. Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy. Biochem Pharmacol. 2021;188:114589.
   PubMed Web of Science ®Google Scholar
• Labib M, Kelley SO. Circulating tumor cell profiling for precision oncology. Mol Oncol. 2021;15(6):1622–1646.
   PubMed Web of Science ®Google Scholar
• Zhang H, Yuan F, Qi Y, et al. Circulating tumor cells for glioma. Front Oncol. 2021;11:607150.
   PubMed Web of Science ®Google Scholar
• Huang C, Lin X, He J, et al. Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2021;161(2):613–620.
   PubMed Web of Science ®Google Scholar
• Yousefi M, Ghaffari P, Nosrati R, et al. Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer. Cell Oncol (Dordr). 2020;43(1):31–49.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li J, Cao L, et al. Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol. 2012;39(4):449–460.
   PubMed Web of Science ®Google Scholar
• Li X, Wang H, Li T, et al. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma. Curr Probl Cancer. 2020;44(2):100516.
   PubMed Web of Science ®Google Scholar
• Ahn JC, Teng PC, Chen PJ, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology. 2021;73(1):422–436.
   PubMed Web of Science ®Google Scholar
• Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol. 2000;156(1):57–63.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Park HA, Brown SR, Kim Y. Cellular mechanisms of circulating tumor cells during breast cancer metastasis. Int J Mol Sci. 2020;21(14):5040.
   Web of Science ®Google Scholar
• Cho HY, Choi JH, Lim J, et al. Microfluidic chip-based cancer diagnosis and prediction of relapse by detecting circulating tumor cells and circulating cancer stem cells. Cancers (Basel). 2021;13(6):1385.
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhou H, Lu K, et al. Circulating tumor cells in the clinical cancer diagnosis. Clin Transl Oncol. 2020;22(3):279–282.
   PubMed Web of Science ®Google Scholar
• Al Ustwani O, Iancu D, Yacoub R, et al. Detection of circulating tumor cells in cancers of biliary origin. J Gastrointest Oncol. 2012;3:97–104.
   PubMedGoogle Scholar
• Yang JD, Campion MB, Liu MC, et al. Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology. 2016;63(1):148–158.
   PubMed Web of Science ®Google Scholar
• Gopinathan P, Chiang NJ, Bandaru A, et al. Exploring circulating tumor cells in cholangiocarcinoma using a novel glycosaminoglycan probe on a microfluidic platform. Adv Healthc Mater. 2020;9(10):e1901875.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhang Z, Zhou H, et al. Preoperative circulating tumor cells to predict microvascular invasion and dynamical detection indicate the prognosis of hepatocellular carcinoma. BMC Cancer. 2020;20(1):1047.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Ofuji K, Hiramatsu K, et al. Circulating tumor cells detected with a microcavity array predict clinical outcome in hepatocellular carcinoma. Cancer Med. 2021;10(7):2300–2309.
   PubMed Web of Science ®Google Scholar
• Sun YF, Wang PX, Cheng JW, et al. Postoperative circulating tumor cells: an early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. Cancer Cytopathol. 2020;128(10):733–745.
   PubMed Web of Science ®Google Scholar
• Fan JL, Yang YF, Yuan CH, et al. Circulating tumor cells for predicting the prognostic of patients with hepatocellular carcinoma: a meta analysis. Cell Physiol Biochem. 2015;37(2):629–640.
   PubMedGoogle Scholar
• Wu X, Yang C, Yu H, et al. The predictive values of serum dickkopf-1 and circulating tumor cells in evaluating the efficacy of transcatheter arterial chemoembolization treatment on hepatocellular carcinoma. Medicine (Baltimore). 2019;98(30):e16579.
   PubMed Web of Science ®Google Scholar